These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 8195041

  • 1. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.
    Révész L, Edgren MR, Wainson AA.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):403-6. PubMed ID: 8195041
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
    Palomares T, Bilbao P, del Olmo M, Castro B, Calle Y, Alonso-Varona A.
    Melanoma Res; 1999 Jun 15; 9(3):233-42. PubMed ID: 10465578
    [Abstract] [Full Text] [Related]

  • 3. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
    Thrall BD, Raha GA, Springer DL, Meadows GG.
    Pigment Cell Res; 1991 Dec 15; 4(5-6):234-9. PubMed ID: 1823927
    [Abstract] [Full Text] [Related]

  • 4. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
    Prezioso JA, FitzGerald GB, Wick MM.
    J Invest Dermatol; 1992 Sep 15; 99(3):289-93. PubMed ID: 1512464
    [Abstract] [Full Text] [Related]

  • 5. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995 Sep 15; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

  • 6. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW, Beyers KL.
    Br J Cancer; 1993 Dec 15; 68(6):1071-9. PubMed ID: 8260357
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
    Dorr RT, Liddil JD, Soble MJ.
    Invest New Drugs; 1986 Dec 15; 4(4):305-13. PubMed ID: 3583642
    [Abstract] [Full Text] [Related]

  • 8. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
    Kable EP, Favier D, Parsons PG.
    Cancer Res; 1989 May 01; 49(9):2327-31. PubMed ID: 2706620
    [Abstract] [Full Text] [Related]

  • 10. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P, Loh SY, Kelland LR, Harrap KR.
    Int J Cancer; 1993 Nov 11; 55(5):848-56. PubMed ID: 8244583
    [Abstract] [Full Text] [Related]

  • 11. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 12. Modulation of glutathione level in cultured human melanoma cells.
    Karg E, Brötell H, Rosengren E, Rorsman H.
    Acta Derm Venereol; 1989 Jan 01; 69(2):137-41. PubMed ID: 2564231
    [Abstract] [Full Text] [Related]

  • 13. Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts.
    Guichard M, Lespinasse F, Malaise EP.
    Radiat Res; 1986 Jan 01; 105(1):115-25. PubMed ID: 3945723
    [Abstract] [Full Text] [Related]

  • 14. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

  • 15. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K, Shrieve DC.
    J Natl Cancer Inst; 1987 Oct 01; 79(4):811-5. PubMed ID: 3477662
    [Abstract] [Full Text] [Related]

  • 16. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.
    Yu NY, Brown JM.
    Int J Radiat Oncol Biol Phys; 1984 Aug 01; 10(8):1265-9. PubMed ID: 6236185
    [Abstract] [Full Text] [Related]

  • 17. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
    Bier H.
    Laryngorhinootologie; 1990 Jan 01; 69(1):16-20. PubMed ID: 2310456
    [Abstract] [Full Text] [Related]

  • 18. Exogenous glutathione attenuates the antiproliferative effect of buthionine sulfoximine.
    Kang YJ.
    Toxicology; 1994 Mar 11; 88(1-3):177-89. PubMed ID: 8160199
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 11; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 20. Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats.
    Kang YJ, Uthus EO.
    Biochem Pharmacol; 1996 Feb 23; 51(4):567-70. PubMed ID: 8619904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.